David P Kao1, JoAnn Lindenfeld1, Dendy Macaulay2, Howard G Birnbaum3, John L Jarvis3, Urvi S Desai3, Robert L Page4. 1. 1 Division of Cardiology, Department of Medicine, University of Colorado School of Medicine , Aurora, Colorado. 2. 2 Analysis Group, Inc., New York, New York. 3. 3 Analysis Group, Inc., Boston, Massachusetts. 4. 4 Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences , Aurora, Colorado.
Abstract
BACKGROUND: Telehealth has the potential to improve chronic disease management and outcomes, but data regarding direct benefit of telehealth in patients with heart failure (HF) have been mixed. The objective of this study was to determine whether the Health Buddy Program (HBP) (Bosch Healthcare, Palo Alto, CA), a content-driven telehealth system coupled with care management, is associated with improved outcomes in Medicare beneficiaries with HF. MATERIALS AND METHODS: This was a retrospective cohort study of 623 Medicare beneficiaries with HF offered HBP enrollment compared with a propensity score-matched control group of Medicare beneficiaries with HF from the Medicare 5% sample. Associations between availability of the HBP and all-cause mortality, hospitalization, hospital days, and emergency department visits were evaluated. RESULTS: Beneficiaries offered enrollment in the HBP had 24.9% lower risk-adjusted all-cause mortality over 3 years of follow-up (hazard ratio [HR] = 0.75; 95% confidence interval [CI], 0.63-0.89; p = 0.001). Patients who used the HBP at least once (36.9%) had 57.2% lower mortality compared with matched controls (HR = 0.43; 95% CI, 0.31-0.60; p < 0.001), whereas patients who did not use the HBP had no significant difference in survival (HR = 0.96; 95% CI, 0.78-1.19; p = 0.69). Patients offered the HBP also had fewer hospital admissions following enrollment (Δ = -0.05 admissions/quarter; p = 0.011), which was primarily observed in patients who used the HBP at least once (Δ = -0.10 admissions/quarter; p < 0.001). CONCLUSIONS: The HBP, a content-driven telehealth system coupled with care management, was associated with significantly better survival and reduced hospitalization in Medicare beneficiaries with HF. Prospective study is warranted to determine the mechanism of this association and opportunities for optimization.
BACKGROUND: Telehealth has the potential to improve chronic disease management and outcomes, but data regarding direct benefit of telehealth in patients with heart failure (HF) have been mixed. The objective of this study was to determine whether the Health Buddy Program (HBP) (Bosch Healthcare, Palo Alto, CA), a content-driven telehealth system coupled with care management, is associated with improved outcomes in Medicare beneficiaries with HF. MATERIALS AND METHODS: This was a retrospective cohort study of 623 Medicare beneficiaries with HF offered HBP enrollment compared with a propensity score-matched control group of Medicare beneficiaries with HF from the Medicare 5% sample. Associations between availability of the HBP and all-cause mortality, hospitalization, hospital days, and emergency department visits were evaluated. RESULTS: Beneficiaries offered enrollment in the HBP had 24.9% lower risk-adjusted all-cause mortality over 3 years of follow-up (hazard ratio [HR] = 0.75; 95% confidence interval [CI], 0.63-0.89; p = 0.001). Patients who used the HBP at least once (36.9%) had 57.2% lower mortality compared with matched controls (HR = 0.43; 95% CI, 0.31-0.60; p < 0.001), whereas patients who did not use the HBP had no significant difference in survival (HR = 0.96; 95% CI, 0.78-1.19; p = 0.69). Patients offered the HBP also had fewer hospital admissions following enrollment (Δ = -0.05 admissions/quarter; p = 0.011), which was primarily observed in patients who used the HBP at least once (Δ = -0.10 admissions/quarter; p < 0.001). CONCLUSIONS: The HBP, a content-driven telehealth system coupled with care management, was associated with significantly better survival and reduced hospitalization in Medicare beneficiaries with HF. Prospective study is warranted to determine the mechanism of this association and opportunities for optimization.
Authors: Friedrich Koehler; Sebastian Winkler; Michael Schieber; Udo Sechtem; Karl Stangl; Michael Böhm; Herbert Boll; Simone S Kim; Kerstin Koehler; Stephanie Lücke; Marcus Honold; Peter Heinze; Thomas Schweizer; Martin Braecklein; Bridget-Anne Kirwan; Goetz Gelbrich; Stefan D Anker Journal: Eur J Heart Fail Date: 2010-12 Impact factor: 15.534
Authors: Bram L T Ramaekers; Josianne J Janssen-Boyne; Anton P M Gorgels; Hubertus J M Vrijhoef Journal: Telemed J E Health Date: 2009 Jul-Aug Impact factor: 3.536
Authors: Sally C Inglis; Robyn A Clark; Finlay A McAlister; Jocasta Ball; Christian Lewinter; Damien Cullington; Simon Stewart; John Gf Cleland Journal: Cochrane Database Syst Rev Date: 2010-08-04
Authors: Bradi B Granger; Karl Swedberg; Inger Ekman; Christopher B Granger; Bertil Olofsson; John J V McMurray; Salim Yusuf; Eric L Michelson; Marc A Pfeffer Journal: Lancet Date: 2005-12-10 Impact factor: 79.321
Authors: Richard S Schofield; Sharoen E Kline; Carsten M Schmalfuss; Hollie M Carver; Juan M Aranda; Daniel F Pauly; James A Hill; Britta I Neugaard; Neale R Chumbler Journal: Telemed J E Health Date: 2005-02 Impact factor: 3.536
Authors: R I Horwitz; C M Viscoli; L Berkman; R M Donaldson; S M Horwitz; C J Murray; D F Ransohoff; J Sindelar Journal: Lancet Date: 1990-09-01 Impact factor: 79.321
Authors: Laura P Gelfman; Marie Bakitas; Lynne Warner Stevenson; James N Kirkpatrick; Nathan E Goldstein Journal: J Palliat Med Date: 2017-05-12 Impact factor: 2.947
Authors: Oliver T Nguyen; Amir Alishahi Tabriz; Jinhai Huo; Karim Hanna; Christopher M Shea; Kea Turner Journal: J Med Internet Res Date: 2021-05-05 Impact factor: 5.428
Authors: Husayn Marani; Hayley Baranek; Howard Abrams; Michael McDonald; Megan Nguyen; Juan Duero Posada; Heather Ross; Toni Schofield; James Shaw; R Sacha Bhatia Journal: J Comorb Date: 2020-06-18